Home>Topics>>Esperion Therapeutics: Another IPO After Pfizer Abandons The Only Drug In Its Pipeline

Esperion Therapeutics: Another IPO After Pfizer Abandons The Only Drug In Its Pipeline

IPO Analysis from Seeking Alpha

Wed, 26 Jun 2013

By Chad Brand : This morning I saw Esperion Therapeutics (NASDAQ: ESPR ) scroll by on the CNBC ticker tape and did a double-take. This biotech company was one of my better investments in the early 2000s and it was ultimately acquired by Pfizer (NYSE: PFE ) for more than $1 billion in 2004. Since I ...

Related Videos

  1. Tech Opportunities Powering Up for Health Care

    Wed, 5 Jun 2013

    A sea change of trends in the health-care industry will be a boon for IT investments, and the firms that can limit costs are the growth businesses of tomorrow, says Fidelity's Eddie Yoon.

  2. The Friday Five

    Fri, 3 May 2013

    Five stats from the market and the stories behind them. This week: content kings, patent cliffs, and 30,000 head to Omaha.

  3. First Day Pop Doesn't Spell Long-Term Success for IPOs

    Tue, 15 May 2012

    Recent tech IPOs have had great first days, but performance has lagged since then, says Morningstar's James Krapfel.

  4. Individual Investors: Handle IPOs With Care

    Tue, 29 Oct 2013

    In a possibly frothy market, investors looking to ride an IPO need to be very cautious and focus on the fundamentals, says Morningstar's Jim Krapfel.

Content Partners